{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:27:09Z","timestamp":1792553229961,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.amjcard.2026.03.068","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:29:25Z","timestamp":1775057365000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Sacubitril\/Valsartan and Prevention of Chemotherapy-Induced Cardiac Dysfunction: Meta-analysis of Randomized Trials"],"prefix":"10.1016","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7890-2615","authenticated-orcid":false,"given":"Ramon","family":"Huntermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eduarda","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Gomes","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Peres","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Muniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Ara\u00fajo","family":"de Lucena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane Yoshie","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edielle S.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline de Oliveira Fischer","family":"Bacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.amjcard.2026.03.068_bib0001","first-page":"1819","article-title":"Burden and prognostic impact of cardiovascular disease in patients with cancer","volume":"109","author":"Raisi-Estabragh","year":"2023","journal-title":"Heart Br Card Soc"},{"issue":"2","key":"10.1016\/j.amjcard.2026.03.068_bib0002","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaccao.2024.02.001","article-title":"Cardiovascular concerns, cancer treatment, and biological and chronological aging in Cancer: JACC Family Series","volume":"6","author":"Ioffe","year":"2024","journal-title":"JACC CardioOncology"},{"issue":"1","key":"10.1016\/j.amjcard.2026.03.068_bib0003","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.23.01779","article-title":"Cardiac dysfunction among breast cancer survivors: role of cardiotoxic therapy and cardiovascular risk factors","volume":"43","author":"Bostany","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.amjcard.2026.03.068_bib0004","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/jnci\/djae107","article-title":"Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors","volume":"116","author":"Vo","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.amjcard.2026.03.068_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115361","article-title":"Navigating cancer therapy induced cardiotoxicity: from pathophysiology to treatment innovations","volume":"211","author":"Tetterton-Kellner","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"issue":"27","key":"10.1016\/j.amjcard.2026.03.068_bib0006","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","article-title":"A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer","volume":"43","author":"Lewinter","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.amjcard.2026.03.068_bib0007","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10741-023-10328-z","article-title":"ACEI\/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis","volume":"28","author":"Gao","year":"2023","journal-title":"Heart Fail Rev"},{"issue":"21","key":"10.1016\/j.amjcard.2026.03.068_bib0008","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","article-title":"Prospective, randomized controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE Trial","volume":"148","author":"Henriksen","year":"2023","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.amjcard.2026.03.068_bib0009","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1161\/CIR.0000000000001354","article-title":"Speckle-tracking strain echocardiography for the assessment of left ventricular structure and function: a scientific statement from the American Heart Association","volume":"152","author":"Mihos","year":"2025","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.amjcard.2026.03.068_bib0010","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.echo.2025.07.007","article-title":"Clinical applications of strain Echocardiography: a Clinical consensus statement from the American Society of Echocardiography developed in collaboration with the European Association of Cardiovascular Imaging of the European Society of Cardiology","volume":"38","author":"Thomas","year":"2025","journal-title":"J Am Soc Echocardiogrr"},{"key":"10.1016\/j.amjcard.2026.03.068_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.125.073322","article-title":"Sacubitril-Valsartan for the prevention of anthracycline cardiotoxicity in patients with elevated cardiac troponin I concentration during chemotherapy: a double-blind randomized placebo-controlled clinical trial: the SARAH Trial","author":"Bonatto","year":"2025","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.amjcard.2026.03.068_bib0012","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/CIRCULATIONAHA.125.076616","article-title":"Sacubitril\/Valsartan and prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA II randomized clinical trial","volume":"152","author":"Omland","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.03.068_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.3758","article-title":"Primary cardioprotective effect of sacubitril\/valsartan in breast cancer patients receiving adjuvant therapy","author":"Hsu","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.amjcard.2026.03.068_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101628","article-title":"Effect of Sacubitril\/Valsartan or Enalapril on left ventricular function in patients with hematologic malignancies treated with bone marrow transplantation: a randomized controlled trial","volume":"4","author":"Katogiannis","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.amjcard.2026.03.068_bib0015","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5","year":"2024"},{"key":"10.1016\/j.amjcard.2026.03.068_bib0016","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.amjcard.2026.03.068_bib0017","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.amjcard.2026.03.068_bib0018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.amjcard.2026.03.068_bib0019","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.amjcard.2026.03.068_bib0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","article-title":"Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America","volume":"31","author":"Bloom","year":"2025","journal-title":"J Card Fail."},{"issue":"16","key":"10.1016\/j.amjcard.2026.03.068_bib0021","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","article-title":"Cardiovascular Imaging in Contemporary Cardio-oncology: a scientific statement from the American Heart Association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.amjcard.2026.03.068_bib0022","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry","volume":"41","author":"L\u00f3pez-Send\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.amjcard.2026.03.068_bib0023","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.3390\/cancers17193225","article-title":"Cancer-induced cardiac dysfunction: mechanisms, diagnostics, and emerging therapeutics in the era of onco-cardiology","volume":"17","author":"Saha","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.amjcard.2026.03.068_bib0024","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/cancers15010312","article-title":"Neprilysin inhibition in the prevention of anthracycline-induced cardiotoxicity","volume":"15","author":"Sobiborowicz-Sadowska","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.amjcard.2026.03.068_bib0025","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10741-025-10495-1","article-title":"The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity","volume":"30","author":"Mecinaj","year":"2025","journal-title":"Heart Fail Rev"},{"issue":"5","key":"10.1016\/j.amjcard.2026.03.068_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2025.102987","article-title":"Sacubitril-valsartan in Cancer therapy-induced heart failure: a systematic review and meta-analysis of functional and hemodynamic parameters","volume":"50","author":"H\u00fcntermann","year":"2025","journal-title":"Curr Probl Cardiol"},{"issue":"2","key":"10.1016\/j.amjcard.2026.03.068_bib0027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-024-00691-z","article-title":"Sacubitril-Valsartan lowers atrial fibrillation recurrence and left atrial volume post-catheter ablation: systematic review and meta-analysis","volume":"25","author":"de Lucena","year":"2025","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"issue":"2","key":"10.1016\/j.amjcard.2026.03.068_bib0028","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/cvr\/cvx078","article-title":"Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity","volume":"114","author":"Lother","year":"2018","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.amjcard.2026.03.068_bib0029","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/echo.14944","article-title":"Role of myocardial strain imaging in surveillance and management of cancer therapeutics-related cardiac dysfunction: a systematic review","volume":"38","author":"McGregor","year":"2021","journal-title":"Echocardiogr Mt Kisco N"},{"issue":"17","key":"10.1016\/j.amjcard.2026.03.068_bib0030","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926002146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926002146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:17:37Z","timestamp":1779970657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926002146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"alternative-id":["S0002914926002146"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.03.068","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sacubitril\/Valsartan and Prevention of Chemotherapy-Induced Cardiac Dysfunction: Meta-analysis of Randomized Trials","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.03.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}